MX2020013103A - Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia. - Google Patents

Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.

Info

Publication number
MX2020013103A
MX2020013103A MX2020013103A MX2020013103A MX2020013103A MX 2020013103 A MX2020013103 A MX 2020013103A MX 2020013103 A MX2020013103 A MX 2020013103A MX 2020013103 A MX2020013103 A MX 2020013103A MX 2020013103 A MX2020013103 A MX 2020013103A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
methods
leukemia relapse
relapse
Prior art date
Application number
MX2020013103A
Other languages
English (en)
Inventor
Yang Liu
Pan Zheng
Martin Devenport
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Publication of MX2020013103A publication Critical patent/MX2020013103A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al uso de una proteína CD24 para prevenir o tratar la recaída de un cáncer en un sujeto. La presente invención también se refiere al uso de una proteína CD24 para reducir la actividad de células madre cancerosas.
MX2020013103A 2018-06-04 2019-06-03 Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia. MX2020013103A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862680218P 2018-06-04 2018-06-04
US201862739742P 2018-10-01 2018-10-01
US201862739719P 2018-10-01 2018-10-01
PCT/US2019/035205 WO2019236474A1 (en) 2018-06-04 2019-06-03 Methods of use of cd24 for the prevention and treatment of leukemia relapse

Publications (1)

Publication Number Publication Date
MX2020013103A true MX2020013103A (es) 2021-05-12

Family

ID=68770596

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020013103A MX2020013103A (es) 2018-06-04 2019-06-03 Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.
MX2020013100A MX2020013100A (es) 2018-06-04 2019-06-03 Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020013100A MX2020013100A (es) 2018-06-04 2019-06-03 Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.

Country Status (15)

Country Link
US (2) US11911441B2 (es)
EP (2) EP3802583A4 (es)
JP (2) JP2021527066A (es)
KR (2) KR20210018294A (es)
CN (2) CN112512640A (es)
AU (2) AU2019282044A1 (es)
BR (2) BR112020024659A2 (es)
CA (2) CA3102372A1 (es)
CL (2) CL2020003169A1 (es)
IL (2) IL279204A (es)
MA (2) MA52810A (es)
MX (2) MX2020013103A (es)
SG (2) SG11202011963UA (es)
TW (2) TW202012015A (es)
WO (2) WO2019236474A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013103A (es) * 2018-06-04 2021-05-12 Oncoimmune Inc Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.
US20230108492A1 (en) * 2020-02-10 2023-04-06 Oncoimmune, Inc. Methods of use of soluble cd24 for treating viral pneumonia
WO2023205742A1 (en) * 2022-04-20 2023-10-26 OncoC4, Inc. Mutant cd24 proteins and uses thereof for prophylaxis and treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CA2705353C (en) * 2007-11-14 2017-07-25 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
US8808697B2 (en) * 2010-04-28 2014-08-19 Oncoimmune, Inc. Methods of use of soluble CD24 for therapy of rheumatoid arthritis
CN102250828B (zh) * 2010-11-10 2014-11-05 北京大学 Cd24及cd24抗体的新用途
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
EP3215539A4 (en) * 2014-11-06 2018-05-23 Children's Research Institute, Children's National Immunotherapeutics for cancer and autoimmune diseases
BR112017022394A2 (pt) * 2015-05-07 2018-07-17 Oncoimmune Inc uso de cd24 para diminuir níveis de colesterol das lipoproteínas de baixa densidade
KR20180120145A (ko) * 2016-02-02 2018-11-05 온코이뮨, 아이앤씨. 렙틴-결핍 병태를 치료하기 위한 cd24 단백질의 용도
MX2020013103A (es) * 2018-06-04 2021-05-12 Oncoimmune Inc Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.
EP4087406A4 (en) * 2020-01-08 2024-01-10 PureTech LYT, Inc. VESICLE COMPOSITIONS FOR ORAL ADMINISTRATION

Also Published As

Publication number Publication date
JP2021527056A (ja) 2021-10-11
AU2019282530A1 (en) 2021-01-07
KR20210018294A (ko) 2021-02-17
TW202015753A (zh) 2020-05-01
AU2019282044A1 (en) 2021-01-07
EP3801773A1 (en) 2021-04-14
SG11202011963UA (en) 2020-12-30
EP3802583A4 (en) 2022-03-16
US20210268061A1 (en) 2021-09-02
BR112020024659A2 (pt) 2021-03-09
EP3802583A1 (en) 2021-04-14
WO2019236474A1 (en) 2019-12-12
MA52811A (fr) 2022-03-16
BR112020024683A2 (pt) 2021-03-09
MX2020013100A (es) 2021-02-17
SG11202011964SA (en) 2020-12-30
US20210228680A1 (en) 2021-07-29
EP3801773A4 (en) 2022-03-16
WO2019236472A1 (en) 2019-12-12
MA52810A (fr) 2021-04-14
IL279205A (en) 2021-01-31
CN112512640A (zh) 2021-03-16
CA3102374A1 (en) 2019-12-12
TW202012015A (zh) 2020-04-01
KR20210021317A (ko) 2021-02-25
CL2020003169A1 (es) 2021-06-11
IL279204A (en) 2021-01-31
CN112752766A (zh) 2021-05-04
CL2020003168A1 (es) 2021-06-11
JP2021527066A (ja) 2021-10-11
CA3102372A1 (en) 2019-12-12
US11911441B2 (en) 2024-02-27

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
WO2017096309A8 (en) Methods of treatment of malignancies
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
SA521422089B1 (ar) c أجسام مضادة مكتسبة للسمة البشرية ضد مجموعة
ZA201802966B (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2017011834A (es) Macrociclos peptidomimeticos y usos de los mismos.
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
MX2021005761A (es) Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados.
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2018006531A (es) Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada.
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
MX2020013103A (es) Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
EP4353320A3 (en) Blood plasma and plasma fractions as therapy for tumor growth and progression
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
WO2018208954A3 (en) Peptidomimetic macrocycles and uses thereof
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.